• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Vernakalant Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764554

MBS5764554 is an inhibitor targeting Vernakalant. Vernakalant (RSD-1235) is a mixed ion channel blocker. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Vernakalant, Inhibitor
Full Product Name
Vernakalant
Product Synonym Names
RSD1235
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
349.46
Solubility
DMSO: Soluble
(<1mg/ refers to the product slightly soluble or insoluble)
Formula
C20H31NO4
SMILES
COc(ccc(CCO[C@H](CCCC1)[C@@H]1N(CC1)C[C@@H]1O)c1)c1OC
CAS Number
794466-70-9
In Vitro
Vernakalant can terminate acute atrial fibrillation (AF) in humans at 2 to 5mg/kg and maybe more atrial-selective than available agents [1].

Product References and Citations for Vernakalant, inhibitor

Dorian, Paul MD et al. The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. Journal of Cardiovascular Pharmacology:July 2007 - Volume 50 -Issue 1 - pp 35-40.
Dorian, Paul MD et al. The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. Journal of Cardiovascular Pharmacology:July 2007 - Volume 50 -Issue 1 - pp 35-40.
Jodene Eldstrom et al. The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels. Molecular Pharmacology December 2007 vol. 72 no. 6 1522-1534
Jodene Eldstrom et al. The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels. Molecular Pharmacology December 2007 vol. 72 no. 6 1522-1534
Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21(127):119-22.
Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21(127):119-22.
Carina Blomstrom-Lundqvist, Per Blomstrom. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity. Expert Opin Drug Saf. 2012 Jul;11(4):671-9. Epub 2012 May 26.
Carina Blomstrom-Lundqvist, Per Blomstrom. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity. Expert Opin Drug Saf. 2012 Jul;11(4):671-9. Epub 2012 May 26.

Other Notes

Small volumes of Vernakalant, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000